Roche Group Development Pipeline 2023 Q2 Update

Comprehensive overview of Roche's pharmaceutical development portfolio as of July 2023, including new molecular entities (NMEs) and additional indications (AIs) across oncology, immunology, neuroscience, and other therapeutic areas. The pipeline shows progress with approvals, new entries into development phases, and removals, spanning research through marketed products across Roche Pharma, Genentech, and affiliated entities.